SHERIDAN, WYOMING – July 25, 2025 – A recent string of awkward and, at times, insensitive employee layoff notifications in the biopharma industry is sparking serious concerns around internal communications, HR protocol, and employer branding amid rising workforce reductions.
SHERIDAN, WYOMING – July 25, 2025 – Roche has received CE Mark certification for its Elecsys® pTau181 blood test, marking a pivotal advancement in Alzheimer’s diagnostics by introducing the first IVDR-certified in-vitro diagnostic test to help rule out Alzheimer’s-associated amyloid pathology.
SHERIDAN, WYOMING – July 25, 2025 – Roche has announced a significant step in the modernization of its capital structure, as its Board of Directors proposes to exchange the company's non-voting equity securities ("Genussscheine") for newly issued participation certificates. The proposal, which will be submitted to shareholders for approval at the 2026 Annual General Meeting (AGM), aims to align Roche’s capital instruments with current Swiss corporate law and modern market practices.
SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has scheduled the announcement of its financial results for the second quarter ended June 30, 2025, for Thursday, August 7, 2025, after market close. The musculoskeletal technology leader will publish the earnings release on its investor relations website at www.investors.globusmedical.com.
Investor Call Scheduled for August 7
SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. (NYSE: GMED), a global leader in musculoskeletal solutions, today announced a significant strategic initiative with the authorization of a share repurchase program of up to $500 million of the company’s outstanding common stock. The move underscores Globus Medical’s confidence in its long-term business fundamentals and commitment to delivering sustained value for shareholders.
Strategic Response to Market Valuation Trends
SHERIDAN, WYOMING – July 21, 2025 – KaVo, the renowned dental technology manufacturer based in Biberach, Germany, is reaffirming its long-standing commitment to excellence—this time by embedding sustainability at the core of its corporate strategy. With a newly certified environmental management system and a multi-stage sustainability plan, KaVo is strengthening its role as a responsible industry leader focused on environmental protection and operational efficiency.
Certified Environmental Management Anchored in Corporate Policy
SHERIDAN, WYOMING – July 21, 2025 – Carestream Dental has secured a significant milestone as its CS 9600 and CS 8200 3D Family CBCT systems have been officially certified by the Digital Dentistry Society (DDS). As the first—and currently only—CBCT imaging systems to earn this distinguished certification, the recognition underscores Carestream Dental’s leadership in digital dental innovation and clinical excellence.
A Rigorous Certification Validates Clinical and Technological Leadership
SHERIDAN, WYOMING – July 21, 2025 – Illinois' life sciences industry continues to demonstrate resilience and growth, underlining the state's standing as a regional powerhouse in biopharma employment. According to 2024 data from BIO and TEConomy Partners, Illinois employed 93,402 bioscience professionals across 4,926 businesses, marking a 7.5% increase in employment since 2019 — a growth trajectory that positions the state as a key hub within the BioMidwest Hotbed.
Steady Hiring Momentum in 2025
SHERIDAN, WYOMING – July 21, 2025 – Facing industry-wide uncertainty and hiring slowdowns, biopharma companies are increasingly turning to fractional roles to fill critical talent gaps—an emerging trend reshaping workforce strategies across the sector. Recent insights from recruiters and professionals reveal a growing openness to flexible, project-based roles that offer companies agility while providing experienced professionals with continued engagement in the field.
Fractional Work Gains Traction Amid Market Challenges
SHERIDAN, WYOMING – July 21, 2025 – Sarepta Therapeutics has entered a critical phase of uncertainty after reports surfaced that the U.S. Food and Drug Administration (FDA) is considering requesting a halt to all shipments of its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys. The potential move follows the disclosure of a third patient death associated with the company's underlying gene therapy platform.
FDA Scrutiny Intensifies After Third Death Linked to Platform